Jonathan Chernoff works with Temple University Health System and Temple University leadership to guide Fox Chase into the future of cancer care. A molecular oncologist and medical oncologist, he helps Fox Chase focus on areas that best leverage the institution’s strengths in scientific development.
Martin Edelman’s research focuses on interdisciplinary and multimodality treatment of lung cancer with the goal of translating laboratory observations into practical clinical trials. His role at Fox Chase is to facilitate interactions between laboratory and clinical investigators.
Carolyn Y. Fang studies how psychosocial and behavioral factors influence cancer risk and outcomes, particularly in underserved populations. Her work has made significant contributions to informing evidence-based approaches for addressing cancer health disparities.
As Associate Director for System Integration, Erica Golemis works with Fox Chase and Temple scientists to develop relationships that will lead Fox Chase into the future. As chair of the Department of Cancer and Cell Biology at the Lewis Katz School of Medicine, she focuses on identifying and supporting research synergies that advance cancer research and cancer care.
John Gricoski is responsible for administration of the center, including oversight of research operating and capital budgets, and laboratory space planning. He also manages the NCI Cancer Center Support Grant. Gricoski has an MBA in finance and is a licensed Pennsylvania CPA.
Camille Ragin’s research focuses on gene-environment interactions and cancer health disparities. Her work applies molecular biomarkers, genomics, and public health tools to cancer research in African American communities and African-descended populations worldwide.
A member of the Blood Cell Development and Function research program, Rall focuses on the intersection of virology, immunology, and neurobiology. As associate director of education and training, Rall oversees all faculty affairs, as well as mentoring and education programs.
As director of the Fels Cancer Institute for Personalized Medicine at Temple, Tomasz Skorski oversees the planning, organization, and direction of the institute’s operations and programs. His lab focuses on determining of the role of DNA repair mechanisms in acute and chronic leukemias.
Margaret von Mehren’s research focuses on developmental therapeutics for sarcomas and gastrointestinal stromal tumors. Her work in this area informs her role as the associate director for clinical research, in which she oversees much of the clinical trials process at Fox Chase.
In his role as scientific director, David Wiest oversees the overall direction of science research at the center. His lab explores the molecular basis for normal and malignant hematopoiesis, with a particular emphasis on T lymphocyte development. He also co-leads the Blood Cell Development and Function research program.
Siddharth Balachandran explores how cells die during host innate-immune responses to viruses and bacteria, and how to exploit these mechanisms for the treatment of human disease, whether inflammatory, infectious, or malignant. He is co-leader of the Blood Cell Development and Function research program.
In his role as scientific director, David Wiest oversees the overall direction of science research at the center. His lab explores the molecular basis for normal and malignant hematopoiesis, with a particular emphasis on T lymphocyte development. He also co-leads the Blood Cell Development and Function research program.
As a scientific director, Margie Clapper facilitates translational research by fostering multidisciplinary collaborations among faculty within the Cancer Prevention and Control research program, which she co-leads, and throughout the center. Her research focuses on the identification of biomarkers of cancer risk and development of new cancer preventive therapies.
Michael Hall’s research focus is in hereditary cancer syndromes, including GI syndromes (Lynch syndrome, pancreatic cancer risk) and hereditary breast/ovarian syndrome, as well as precision medicine and secondary hereditary risks, and cancer prevention. As part of the Risk Assessment program, he maintains diverse multidisciplinary collaborations.
Eti Cukierman’s lab studies the biology of desmoplasia, which plays a central role in epithelial tumor formation. In her leadership role, she works to facilitate clinical collaborations with the goal of testing laboratory-generated hypotheses and translating basic discoveries to the clinic.
The Whetstine laboratory studies how chromatin factors control gene expression and genome stability, and in turn, the impact on cancer drug response and resistance. As director of the Cancer Epigenetics Institute, Whetstine works to promote fundamental discovery in cancer epigenetics while identifying novel biomarkers and therapeutic targets.
Hossein Borghaei’s lab concentrates on the development of new cancer treatments, with an emphasis on the use of immunotherapy and monoclonal antibodies. Borghaei frequently collaborates with scientists outside of Fox Chase in an effort to bring newer immune-based treatments to the clinic.
The goal of the Karanicolas lab is to develop structure-based approaches for controlling protein function using small molecules. Karanicolas and his team use these methods to reactivate disabled tumor suppressors, inhibit cancer-driving RNA-binding proteins, disable key oncogenic kinases, and tune the activity of antibodies used in cancer immunotherapy.